Kevin K. Gordon
Known title: DirectorCIK: 0001218483
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Transaction History
| PGNY | ▲ Buy | Option Exercise | 22,000 | $286K | 9/10/2026 | View on chart |
| PGNY | ▼ Sell | Tax Withholding | 10,500 | $286K | 9/10/2026 | View on chart |
| PGNY | ▼ Sell | Open Market | 11,500 | $321K | 9/10/2026 | View on chart |
| PGNY | ▼ Sell | Open Market | 5,500 | $137K | 5/27/2026 | View on chart |
| PGNY | ▼ Sell | Other | 2,526 | $0 | 5/27/2026 | View on chart |
| PGNY | ▼ Sell | Other | 2,526 | $0 | 5/27/2026 | View on chart |
| PGNY | ▲ Buy | Grant | 6,792 | $0 | 5/21/2026 | View on chart |
| PGNY | ▼ Sell | Open Market | 2,500 | $55K | 8/11/2025 | View on chart |
| PGNY | ▲ Buy | Grant | 8,026 | $0 | 5/22/2025 | View on chart |
| PGNY | ▲ Buy | Grant | 5,147 | $0 | 5/23/2024 | View on chart |
| PGNY | ▼ Sell | Open Market | 2,500 | $90K | 12/11/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 3,654 | $0 | 5/24/2023 | View on chart |
| PGNY | ▼ Sell | Open Market | 1,410 | $54K | 5/24/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 2,900 | $0 | 10/24/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 15,000 | $111K | 6/8/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 15,000 | $278K | 6/8/2022 | View on chart |
| PGNY | ▲ Buy | Grant | 2,210 | $0 | 10/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace
Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.